<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bipolar major depression in adults: Efficacy and adverse effects of antidepressants</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bipolar major depression in adults: Efficacy and adverse effects of antidepressants</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Bipolar major depression in adults: Efficacy and adverse effects of antidepressants</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William V Bobo, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard C Shelton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Keck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H20879315"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The use of antidepressants for acute and maintenance treatment of bipolar depression is controversial because of concerns that these drugs are not effective and may harm patients by causing switches from depression to mania as well as rapid cycling [<a href="#rid1">1-3</a>]. Nevertheless, antidepressants  (<a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">table 1</a>) are the most commonly prescribed drugs for bipolar depression. Studies of bipolar patients in the United States (n = 7760) [<a href="#rid4">4</a>] and Europe (n = 2231) [<a href="#rid5">5</a>] found that an antidepressant had been prescribed for 50 and 81 percent; this may be due in part to the limited efficacy and tolerability of other treatments [<a href="#rid6">6</a>].</p><p>This topic reviews the efficacy of antidepressants for patients with bipolar major depression and the risk of switching polarity. Separate topics discuss antidepressants and the risk of rapid cycling, choosing treatment for adults with bipolar major depression, the general principles of treating bipolar major depression in adults, the efficacy and adverse effects of second-generation antipsychotics for bipolar major depression in adults, investigational approaches to treating bipolar major depression in adults, choosing pharmacotherapy for adults with acute mania and hypomania, choosing maintenance treatment for adults, and choosing pharmacotherapy for pediatric bipolar major depression:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Antidepressants'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/115480.html" rel="external">"Bipolar major depression in adults: General principles of treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16693.html" rel="external">"Bipolar major depression in adults: Efficacy and adverse effects of second-generation antipsychotics"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/115481.html" rel="external">"Bipolar major depression in adults: Investigational and nonstandard approaches to treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/680.html" rel="external">"Bipolar disorder in adults: Choosing maintenance treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/99164.html" rel="external">"Pediatric bipolar major depression: Choosing treatment"</a>.)</p><p></p><p class="headingAnchor" id="H1837258"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H2230949775"><span class="h2">Bipolar disorder</span><span class="headingEndMark"> — </span>Bipolar disorder is a mood disorder that is characterized by episodes of mania  (<a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">table 2</a>), hypomania  (<a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">table 3</a>), and major depression  (<a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">table 4</a>) [<a href="#rid7">7</a>]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes and nearly always experience hypomanic and major depressive episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">"Bipolar disorder in adults: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">"Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3425357449"><span class="h2">Antimanic drug</span><span class="headingEndMark"> — </span>We use the term antimanic drug to refer to medications that can reduce acute symptoms of mania/hypomania, without causing a switch to the opposite polarity. Examples include <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, antiepileptics such as <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, and second-generation antipsychotics such as <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">cariprazine</a>, <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a>, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, and <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>.</p><p class="headingAnchor" id="H14825957"><span class="h1">ROLE OF ANTIDEPRESSANTS</span><span class="headingEndMark"> — </span>Although the efficacy and safety of antidepressants for bipolar depression remains controversial [<a href="#rid8">8,9</a>], there is a limited role for these drugs as adjuncts to antimanic treatments for treating patients with acute episodes of bipolar major depression [<a href="#rid10">10-18</a>]. The choice of a specific treatment regimen for acute treatment of bipolar major depression is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">"Bipolar major depression in adults: Choosing treatment"</a>.)</p><p class="headingAnchor" id="H14825995"><span class="h2">Acute bipolar depression</span><span class="headingEndMark"> — </span>Antidepressants appear to be effective for some patients with acute bipolar major depression, and it is thus reasonable to use adjunctive antidepressants for patients who initially present with bipolar depression or who have responded favorably to these drugs in the past without treatment-emergent affective switching or mood cycle acceleration [<a href="#rid13">13,14</a>]. This approach is consistent with multiple practice guidelines [<a href="#rid12">12,15,17-23</a>].</p><p>By contrast, we suggest that clinicians generally avoid using antidepressants in patients with bipolar major depression who:</p><p class="bulletIndent1"><span class="glyph">●</span>Were previously treated with antidepressants and experienced poor outcomes such as treatment-emergent switching to mania/hypomania, rapid cycling, or acute suicidal ideation and behavior [<a href="#rid12">12,17,24-30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Have concurrent manic symptoms (ie, mixed features), as well as patients with active substance use disorders, which can increase the risk of mood destabilization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recently recovered from a manic or hypomanic episode (eg, within the past two to three months). However, there are no established criteria for using antidepressants after recovery from mania or hypomania, and adjunctive antidepressants may be started sooner in patients whose mania/hypomania is well controlled, whose depression is severe and not responding to antimanic drugs, and who have a prior history of responding well to antidepressants plus antimanic drugs.</p><p></p><p>The efficacy of antidepressants for acute bipolar major depression, and the risk of antidepressant induced mania or hypomania, rapid cycling, and suicidality are discussed elsewhere. (See <a class="local">'Efficacy'</a> below and <a class="local">'Risk of switching to mania'</a> below and  <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Antidepressants'</a> and <a class="local">'Risk of suicidality'</a> below.)</p><p>Patients with bipolar depression who are treated with adjunctive antidepressants should be educated about the signs of treatment-emergent affective switching to mania, hypomania, or mixed features, and about the risk of mood cycle acceleration; patients should also be monitored for these potential complications. These recommendations are especially important for patients who have never received antidepressants but also apply to patients who were successfully treated with antidepressants in the past.</p><p class="headingAnchor" id="H14827161"><span class="h3">Using antimanic drugs to prevent switching</span><span class="headingEndMark"> — </span>For patients with bipolar major depression who are treated with an antidepressant, we recommend that clinicians concurrently prescribe an antimanic drug such as <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, or a second-generation antipsychotic such as <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">lurasidone</a>, or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>. A review of randomized trials concluded that when antidepressants are prescribed, the concurrent use of antimanic drugs reduces the risk of switching to mania [<a href="#rid3">3</a>]. In addition, avoiding antidepressant monotherapy is consistent with multiple practice guidelines [<a href="#rid12">12,15,18,23</a>].</p><p class="headingAnchor" id="H14827215"><span class="h4">Lithium, lamotrigine, valproate, or carbamazepine</span><span class="headingEndMark"> — </span>Prescribing <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> in conjunction with antidepressants can reduce the likelihood of switching from depression to mania [<a href="#rid12">12,17,18</a>]. Evidence for the efficacy of this approach includes the following studies [<a href="#rid31">31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis of 15 randomized trials (n = 2691 patients with bipolar or unipolar depression) found that switching polarity was nearly twice as likely during treatment with <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a>, compared with imipramine plus <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> (51 versus 28 percent) [<a href="#rid32">32</a>]. The risk of switching with tricyclics is discussed further elsewhere in this topic. (See <a class="local">'Antidepressant class and specific drugs'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 26-week randomized trial compared an antidepressant (<a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a> or <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>) with placebo in 366 patients with bipolar depression; the large majority of patients received <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, and/or <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> (the remaining patients received a second-generation antipsychotic). Switching to mania was comparable for adjunctive antidepressants and placebo (10 and 11 percent) [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A national registry study identified bipolar patients who received an antidepressant plus <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> (n &gt;1600), or received antidepressant monotherapy (n &gt;1100) [<a href="#rid34">34</a>]. Patients had not received antidepressants in the year prior to onset of antidepressant treatment, and for each patient, the risk of mania during antidepressant treatment was compared with the risk during the previous year (in the absence of antidepressants). Thus, each patient served as his or her own control. During the first three months of antidepressant therapy, the risk of mania was not elevated in patients treated with concurrent antimanic drugs. However, patients who received antidepressant monotherapy had an increased risk of mania, compared with the previous year when they were not treated with antidepressants (hazard ratio 2.8, 95% CI 1.1-7.2).</p><p></p><p>For patients with bipolar depression who are treated with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, we suggest a target serum concentration between 0.8 to 1.2 mEq/L (0.8 to 1.2 mmol/L); if difficulty with tolerability occurs, we suggest a minimum target serum concentration of 0.6 mEq/L (0.6 mmol/L). In a randomized trial that included treatment with lithium monotherapy (n = 49) and lithium plus <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> (n = 48), patients with a mean serum lithium concentration of 0.6 mEq/L (0.6 mmol/L) did not switch to mania/hypomania [<a href="#rid35">35</a>]. By contrast, patients who switched to mania/hypomania had a lower mean serum level of 0.4 mEq/L (0.4 mmol/L).</p><p class="headingAnchor" id="H14827221"><span class="h4">Second-generation antipsychotics</span><span class="headingEndMark"> — </span>For patients with bipolar major depression who are treated with <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, concomitant <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> can reduce the risk of switching to mania/hypomania:</p><p class="bulletIndent1"><span class="glyph">●</span>An eight-week randomized trial compared <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> with placebo in 423 patients with bipolar I depression and found that treatment-emergent mania was comparable for patients who received the combination and patients who received placebo (7 and 6 percent) [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study enrolled patients with bipolar I depression (n = 114) who initially responded to acute phase therapy with <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> and randomly assigned them to 12 weeks of open-label olanzapine plus fluoxetine or olanzapine monotherapy [<a href="#rid37">37</a>]. Treatment-emergent mania during maintenance therapy was comparable for patients who received olanzapine plus fluoxetine or olanzapine monotherapy (2 and 0 percent).</p><p></p><p>It is not known if <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> reduces the risk of switching from other antidepressants or if other second-generation antipsychotics reduce the risk of antidepressant-induced switching.</p><p class="headingAnchor" id="H14826001"><span class="h3">Avoiding antidepressant monotherapy</span><span class="headingEndMark"> — </span>We suggest that clinicians avoid antidepressant monotherapy in patients with acute or remitted bipolar I or bipolar II major depression [<a href="#rid17">17,38,39</a>]. This approach is consistent with multiple practice guidelines [<a href="#rid12">12,15,18,23</a>]. Combining an antimanic drug with an antidepressant appears to decrease the rate of switching polarity. (See <a class="local">'Using antimanic drugs to prevent switching'</a> above.)</p><p>Some randomized trials suggest that antidepressant monotherapy may be effective and safe for some patients with bipolar disorder [<a href="#rid35">35,40-45</a>], especially bipolar II disorder. However, many of the trials were small, brief in duration, and lacked a placebo control group [<a href="#rid35">35,40-42,45</a>]. As an example:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of two randomized trials, which lasted 12 and 16 weeks, compared antidepressants (<a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> or <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a>) with <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> in patients with bipolar II depression (total n = 223) [<a href="#rid46">46</a>]. Response (eg, reduction of baseline symptoms ≥50 percent) and treatment-emergent switches to mania in the two groups were comparable, but discontinuation of treatment due to side effects was greater with lithium. However, the absence of a placebo control makes it difficult to interpret the results regarding response, and lithium is often not an effective antidepressant agent in shorter-term treatment. In addition, these relatively short trials did not determine switch rates of longer-term treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a relatively large randomized trial that lasted eight weeks and included 239 patients with acute bipolar I or II depression, response was comparable for patients who received either <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a> monotherapy or placebo (55 and 53 percent) [<a href="#rid47">47</a>].</p><p></p><p class="headingAnchor" id="H14826043"><span class="h2">Maintenance treatment</span><span class="headingEndMark"> — </span>For bipolar major depression that remits with an antidepressant plus an antimanic drug, it is unclear how long antidepressants should be continued. Generally, we continue antidepressants for approximately two to four months after remission of the depressive syndrome [<a href="#rid15">15</a>]. However, we attempt to avoid continuation/maintenance treatment with antidepressants in patients with a current course of rapid cycling, a history of antidepressant-associated switch from depression to mania/hypomania or increases in mood cycle frequency, or a history of frequent and/or severe manic episodes, including episodes complicated by psychotic features or suicidal ideation [<a href="#rid17">17,48</a>]. </p><p>Nevertheless, bipolar patients who repeatedly suffer depressive symptoms in the absence of antidepressants may benefit from longer treatment [<a href="#rid12">12,17,49</a>]. In randomized trials that studied antidepressants as maintenance therapy in bipolar disorder, the duration of treatment ranged from 4 to 36 months [<a href="#rid49">49</a>].</p><p>The efficacy of antidepressants for maintenance treatment of bipolar disorder, and the risk of antidepressant induced mania or hypomania, are discussed elsewhere in this topic. (See <a class="local">'Maintenance treatment'</a> below and <a class="local">'During maintenance treatment'</a> below.)</p><p class="headingAnchor" id="H14826056"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>If adjunctive antidepressants are used to treat bipolar major depression, mood symptoms should be assessed for increases in mood cycling, including more frequent depressive symptoms or episodes. The following self-report mood symptom rating scales may help in monitoring patients, but it is not known whether these instruments improve outcomes for patients with bipolar disorder:</p><p class="bulletIndent1"><span class="glyph">●</span>Mood Disorder Questionnaire – This 15-item instrument  (<a class="graphic graphic_table graphicRef53409" href="/z/d/graphic/53409.html" rel="external">table 5</a>) is the most widely used measure that screens for episodes of mania and hypomania [<a href="#rid50">50-53</a>]. However, there is little information about using the Mood Disorder Questionnaire to monitor the efficacy of treatment in bipolar patients and provide measurement based care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient Health Questionnaire – Nine Item (PHQ-9) – This instrument  (<a class="graphic graphic_table graphicRef59307" href="/z/d/graphic/59307.html" rel="external">table 6</a>) has good psychometric properties and is the standard among scales for monitoring symptoms of depression in patients who are receiving treatment for unipolar major depression [<a href="#rid54">54</a>]. Using the PHQ-9 to provide measurement based care is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14860.html" rel="external">"Using scales to monitor symptoms and treat depression (measurement based care)", section on 'Patient Health Questionnaire - Nine Item'</a>.)</p><p></p><p class="headingAnchor" id="H14826069"><span class="h2">Tapering and discontinuing antidepressants</span><span class="headingEndMark"> — </span>Antidepressants should generally be tapered slowly (eg, over two to four weeks) to avoid discontinuation syndrome symptoms and limit the risk of depressive relapses [<a href="#rid55">55</a>]. However, if treatment-emergent symptoms of mania/hypomania occur during antidepressant treatment, the antidepressant should be abruptly stopped and antimanic treatments should be optimized [<a href="#rid12">12</a>]. The discontinuation syndrome and antimanic drugs are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/105323.html" rel="external">"Discontinuing antidepressant medications in adults"</a> and  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="headingAnchor" id="H20879322"><span class="h1">EFFICACY</span></p><p class="headingAnchor" id="H2257087943"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Most patients with bipolar disorder who were treated with antidepressants in randomized trials had bipolar I disorder rather than bipolar II disorder [<a href="#rid56">56</a>]. As an example, a review of 11 antidepressant trials found that the number of patients with bipolar I major depression was 1842, whereas the number with bipolar II major depression was only 227 [<a href="#rid57">57</a>].</p><p>Most antidepressants have not been adequately studied in patients with bipolar major depression, and it is not known whether antidepressants vary in their efficacy. Relatively few head–to-head comparisons of different antidepressants have been conducted in bipolar disorder.</p><p>In patients with bipolar major depression, adjunctive antidepressants may seemingly provide a benefit when none exists. Bipolar disorder is a cyclical condition, and patients are likely to cycle out of mood episodes spontaneously. Thus, patients may emerge from a depressive episode after the addition of an antidepressant due to the course of illness, rather than the antidepressant. In addition, antidepressants may induce rapid cycling in some patients, which can result in a rapid resolution of the depressive episode, often followed by mania, hypomania, or mixed features. These aspects of bipolar disorder may give the illusion of a therapeutic effect.</p><p>The use of antidepressants in patients with rapid cycling is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Antidepressants'</a> and  <a class="medical medical_review" href="/z/d/html/16890.html" rel="external">"Rapid cycling bipolar disorder in adults: Treatment of major depression", section on 'Use of antidepressants'</a>.)</p><p class="headingAnchor" id="H20879330"><span class="h2">Acute treatment</span><span class="headingEndMark"> — </span>For patients with acute bipolar I or bipolar II major depression, short-term (eg, 6 to 12 weeks) augmentation of antimanic drugs with antidepressants appears to provide a small to moderate clinical benefit. The best established antimanic/antidepressant drug combination for treatment of bipolar major depression is <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>.</p><p>Evidence supporting augmentation of antimanic drugs with antidepressants includes meta-analyses of randomized trials with different antidepressants, which collectively provided a small to moderate clinical benefit:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of four randomized trials lasting five to eight weeks compared antidepressants (deprenyl, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a>, or <a class="drug drug_general" data-topicid="10012" href="/z/d/drug information/10012.html" rel="external">tranylcypromine</a>) with placebo in 662 patients; more than 70 percent received concomitant <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> or <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> [<a href="#rid58">58</a>]. After adjusting for the moderate to large heterogeneity across studies, the analysis found that response (reduction of baseline symptoms ≥50 percent) was more than twice as likely to occur with antidepressants than placebo (relative risk 2.3, 95% CI 1.3-4.0).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent meta-analysis of 10 trials lasting 6 to 12 weeks compared antidepressants (<a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a>, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, or <a class="drug drug_general" data-topicid="9762" href="/z/d/drug information/9762.html" rel="external">phenelzine</a>) with placebo in 1432 patients; most of the trials included an antimanic drug [<a href="#rid59">59</a>]. Response was more likely to occur with antidepressants than placebo (relative risk 1.4, 95% CI 1.1-1.8), and the pooled response rate was greater for antidepressants than placebo (45 versus 33 percent of patients). However, the trials were described as heterogeneous with respect to patient characteristics, duration, and additional treatments allowed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third meta-analysis of six trials lasting 6 to 26 weeks compared antidepressants (agomelatine, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, or <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>) with placebo in 1383 patients, all of whom were treated with an antimanic drug [<a href="#rid56">56</a>]. The analysis found that improvement of depressive symptoms was statistically greater with adjunctive antidepressants than placebo, but the clinical effect was small.</p><p></p><p>However, other trials indicate that for patients with acute bipolar I or bipolar II major depression, augmentation of antimanic drugs with antidepressants is not beneficial:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of five trials, lasting 6 to 26 weeks, compared antidepressants (<a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a>, or <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>) with placebo in 906 patients; approximately 90 percent were treated with an antimanic drug [<a href="#rid57">57</a>]. The analysis found that the rate of response in patients treated with adjunctive antidepressants or placebo was comparable (relative risk 1.18, 95% CI 0.99-1.40); heterogeneity across studies was moderate to large.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of 16 open-label or double-blind trials, lasting 6 to 26 weeks, compared antidepressants plus antimanic drugs with antimanic drugs alone in nearly 2300 patients with bipolar depression [<a href="#rid60">60</a>]. The antidepressants included agomelatine, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a>, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, and <a class="drug drug_general" data-topicid="10012" href="/z/d/drug information/10012.html" rel="external">tranylcypromine</a>. The antimanic drugs included <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, and <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>. Response in the group that received adjunctive antidepressants and the group that did not was comparable; heterogeneity across studies was moderate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subsequent to each meta-analysis described in this section, a six-week randomized trial compared <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> (mean dose 27 mg/day) with placebo in 119 patients who were treated with antimanic drugs [<a href="#rid61">61</a>]. Response with adjunctive citalopram and placebo was comparable (48 and 46 percent).</p><p></p><p>The risk of switching from depression to mania or hypomania during acute treatment with antidepressants is discussed elsewhere in this topic. (See <a class="local">'During acute treatment'</a> below.)</p><p class="headingAnchor" id="H337508406"><span class="h3">Olanzapine plus fluoxetine</span><span class="headingEndMark"> — </span>The best established antimanic/antidepressant drug combination for treatment of bipolar major depression is <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> [<a href="#rid62">62</a>]. This specific combination has been more widely studied than any other antimanic/antidepressant drug combination and has demonstrated efficacy in high quality randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>An eight-week trial randomly assigned 788 patients to one of three treatments: <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>/<a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> (mean modal dose 7/39 mg per day), olanzapine monotherapy (mean modal dose 10 mg per day), or placebo [<a href="#rid36">36</a>]. The primary findings were as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Remission occurred in more patients who received <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>/<a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> than olanzapine monotherapy or placebo (49 versus 33 and 25 percent). In addition, switching to mania was similar for the three groups (approximately 6 percent of patients in each group).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discontinuation of treatment due to adverse events occurred in fewer patients who received <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>/<a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> than olanzapine monotherapy (2 versus 9 percent) and was comparable for olanzapine/fluoxetine and placebo (2 and 5 percent). Nevertheless:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Several side effects occurred more often with <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>/<a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> than olanzapine monotherapy, including diarrhea, extrapyramidal symptoms, nausea, orthostatic hypotension, and increased systolic blood pressure.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Several side effects also occurred more often with <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>/<a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> than placebo. As an example, clinically significant weight gain, defined as an increase from baseline ≥7 percent, occurred in more patients who received olanzapine/fluoxetine than placebo (20 versus 0 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A seven-week trial compared <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>/<a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> (mean modal dose 11/38 mg per day) with <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a> monotherapy (mean modal dose 106 mg per day) in 410 patients with bipolar I major depression [<a href="#rid63">63</a>]. Improvement of depressive symptoms and functioning was greater with olanzapine/fluoxetine than lamotrigine, and the incidence of suicidal behavior was less with olanzapine/fluoxetine. In addition, switching to mania was similar for olanzapine/fluoxetine and lamotrigine (4 and 5 percent of patients), as was discontinuation of treatment due to adverse events (8 and 7 percent). Nevertheless, several side effects occurred more often with olanzapine/fluoxetine than lamotrigine, including increased appetite, dry mouth, somnolence, and tremor. Mean weight gain was greater with olanzapine/fluoxetine than lamotrigine (3.1 versus -0.3 kg), as were increases in hemoglobin A1c, low-density lipoprotein cholesterol, prolactin, and triglycerides.</p><p></p><p class="bulletIndent1">The trial continued for another 18 weeks, such that patients were treated for a total of 25 weeks [<a href="#rid64">64</a>]. Improvement of depression over 25 weeks was greater with <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>/<a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a> than <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>, and treatment-emergent mania was comparable (5 and 7 percent of patients). Discontinuation of treatment due to adverse events with olanzapine/fluoxetine and lamotrigine occurred in 18 and 13 percent. Multiple adverse effects occurred more often with olanzapine/fluoxetine than lamotrigine, including increased appetite, dry mouth, somnolence, and tremor, as well as increases in metabolic parameters. Clinically significant weight gain occurred in more patients who received olanzapine/fluoxetine than lamotrigine (34 versus 2 percent of patients).</p><p></p><p class="headingAnchor" id="H672545"><span class="h3">Predictors of response</span><span class="headingEndMark"> — </span>For treatment of acute bipolar major depression with an antidepressant plus an antimanic drug, response may be better if the antimanic drug is a second-generation antipsychotic (eg, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>), rather than a non-antipsychotic such as <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, or <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">lamotrigine</a>. As an example, a meta-analysis of six randomized trials compared antidepressants with placebo in 1383 patients, all of whom were treated with an antimanic drug [<a href="#rid56">56</a>]. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients treated with an antidepressant plus an antipsychotic, compared with placebo plus an antipsychotic (odds ratio 1.9, 95% CI 1.2-3.0). By contrast, response was similar in patients treated with either an antidepressant plus a non-antipsychotic, or placebo plus a non-antipsychotic (odds ratio 1.0, 95% CI 0.7-1.3).</p><p class="headingAnchor" id="H672688"><span class="h3">Bipolar II depression</span><span class="headingEndMark"> — </span>Based upon randomized trials, improvement of acute depressive symptoms with antidepressants is commensurate in bipolar II depression and bipolar I depression [<a href="#rid47">47,65</a>]. As an example, a 26-week randomized trial found that response (reduction of baseline symptoms ≥50 percent) to antidepressants plus antimanic drugs (eg, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>) was comparable in patients with bipolar II depression (n = 54) and patients with bipolar I depression (n = 118) (20 and 25 percent) [<a href="#rid33">33</a>]. However, antidepressant-induced switching to mania may occur less often in patients with bipolar II depression than bipolar I depression. (See <a class="local">'Bipolar I and bipolar II disorder'</a> below.)</p><p class="headingAnchor" id="H20879337"><span class="h2">Maintenance treatment</span><span class="headingEndMark"> — </span>For patients with acute bipolar depression who are treated with an antimanic drug plus an antidepressant and then recover, longer-term maintenance treatment with adjunctive antidepressants does not appear to prevent relapse of any mood episode (depressive plus manic/hypomanic). However, adjunctive antidepressants may reduce the specific risk of depressive relapses:</p><p class="bulletIndent1"><span class="glyph">●</span>One study enrolled 177 patients with an acute episode of bipolar I major depression who were successfully treated with an antimanic drug (eg, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>) plus an antidepressant, and randomly assigned them to continue the antidepressant for 52 or 8 weeks [<a href="#rid66">66</a>]. The primary results included the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There was no statistically significant difference in relapse with any mood episode (depressive plus manic/hypomanic) between the two groups (hazard ratio 0.7, 95% CI 0.4-1.1)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Relapse of manic or hypomanic episodes was also comparable (hazard ratio 2.3, 95% CI 0.9-6.1)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>However, fewer depressive episodes occurred in the group that received 52 weeks of adjunctive antidepressant treatment, compared with 8 weeks (hazard ratio 0.4, 95% CI 0.3-0.8)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of seven trials compared antidepressants plus antimanic drugs (eg, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>) with placebo plus antimanic drugs as maintenance therapy in 532 patients with bipolar I or bipolar II disorder; pharmacotherapy was administered for a minimum of four months [<a href="#rid49">49</a>]. Relapse was less likely to occur in patients who received adjunctive antidepressants than placebo (relative risk 0.70, 95% CI 0.50-0.97).</p><p></p><p>Although randomized trials in patients with bipolar disorder indicate that maintenance treatment with antidepressant monotherapy is comparable to antimanic drug monotherapy in preventing new episodes of major depression, the risk of manic/hypomanic recurrences is greater with antidepressant monotherapy [<a href="#rid49">49</a>]. Thus, antidepressant monotherapy is typically avoided in bipolar disorder due to concerns about treatment-emergent mania. (See <a class="local">'Avoiding antidepressant monotherapy'</a> above and <a class="local">'During maintenance treatment'</a> below.)</p><p class="headingAnchor" id="H20879358"><span class="h1">RISK OF SWITCHING TO MANIA</span><span class="headingEndMark"> — </span>Treatment of bipolar major depression with antidepressants remains controversial because of concerns that these drugs cause patients to switch polarity directly from depression to mania/hypomania or within a short time after the depressive episode has remitted (eg, two to three months [<a href="#rid67">67</a>]) [<a href="#rid1">1,2,17</a>]. However, switching often occurs in bipolar disorder in the absence of antidepressant treatment [<a href="#rid2">2,25</a>], and the evidence indicates that antidepressants may not increase switching during acute or maintenance treatment. As an example, a pooled analysis of randomized trials and observational studies (7915 bipolar patients) found that the risk of mania/hypomania was comparable for patients who were exposed to antidepressants and patients who were not (15 and 14 percent); heterogeneity was not reported [<a href="#rid68">68</a>].</p><p>Although the evidence suggests that antidepressants collectively (as a drug class) do not induce switching polarity, the risk of treatment-emergent mania may nevertheless exist for specific antidepressants; patients who are treated with antidepressant monotherapy; and patient subgroups, including certain genotypes [<a href="#rid12">12,69</a>].</p><p>If manic or hypomanic symptoms emerge during antidepressant treatment, antidepressants should be abruptly stopped and antimanic treatments should be optimized [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p class="headingAnchor" id="H237966"><span class="h2">During acute treatment</span><span class="headingEndMark"> — </span>Acute (eg, 4 to 26 weeks) treatment of bipolar major depression with adjunctive antidepressants does not appear to increase the risk of switching to mania/hypomania [<a href="#rid15">15,19,70</a>], with the exception of tricyclics [<a href="#rid58">58</a>]. Across multiple randomized trials, the proportion of patients who switched polarity during treatment with antidepressants was approximately 4 to 8 percent, similar to the rate seen in patients treated with placebo:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of five randomized trials compared antidepressants (deprenyl, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a>, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, or <a class="drug drug_general" data-topicid="10012" href="/z/d/drug information/10012.html" rel="external">tranylcypromine</a>) with placebo in 779 patients with bipolar depression; approximately 75 percent received concomitant <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> or <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> [<a href="#rid58">58</a>]. Switch rates for the two groups were similar (relative risk 1.0, 95% CI 0.5-2.1), and a pooled analysis found that switch rates for antidepressants and for placebo were 4 and 5 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent meta-analysis of six randomized trials compared antidepressants (<a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a>, or <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>) with placebo in 1026 patients with bipolar major depression; most patients received concomitant treatment with another drug such as <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, or a second-generation antipsychotic [<a href="#rid57">57</a>]. Switch rates were similar (relative risk 1.0, 95% CI 0.6-1.5), and a pooled analysis found that switch rates for antidepressants and for placebo were 8 and 7 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third meta-analysis of six trials lasting 6 to 26 weeks compared newer antidepressants (agomelatine, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, or <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>) with placebo in 1338 patients, all of whom were treated with an antimanic drug [<a href="#rid56">56</a>]. Treatment-emergent mania/hypomania was similar for the two groups (odds ratio 0.9, 95% CI 0.6-1.5), and a pooled analysis found that switch rates for adjunctive antidepressants and placebo were identical (6 percent).</p><p></p><p>In addition, a subsequent, 16-week randomized trial in patients with bipolar II major depression (n = 97) compared <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> plus <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> with lithium monotherapy and found that switching to mania/hypomania was comparable in the two groups (13 and 19 percent) [<a href="#rid35">35</a>].</p><p>However, randomized trials typically exclude sicker bipolar patients, including those with rapid cycling, psychiatric comorbidity (eg, substance use disorder), comorbid general medical disorders, and suicidal ideation and behavior. Thus, these trials may not generalize to many patients; as an example, comorbidity in bipolar disorder appears to be the rule rather than the exception [<a href="#rid71">71,72</a>]. In addition, randomized trials may provide closer monitoring than occurs in routine clinical care, permitting study investigators to discontinue antidepressants prior to onset of full blown manic/hypomanic episodes.</p><p class="headingAnchor" id="H237973"><span class="h2">During maintenance treatment</span><span class="headingEndMark"> — </span>It is not clear whether maintenance treatment with antidepressants plus antimanic drugs in patients with bipolar disorder causes treatment-emergent mania. Long-term treatment (eg, ≥4 months) studies have found inconsistent results:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of five randomized trials (n = 509) compared antidepressants plus antimanic drugs (eg, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>) with placebo plus antimanic drugs; pharmacotherapy was administered for a minimum of four months [<a href="#rid49">49</a>]. The risk of new manic/hypomanic episodes for the two groups was comparable (relative risk 1.3, 95% CI 0.8-2.1). Subgroup analyses suggested that the risk of mania and hypomania was greater with older antidepressants such as tricyclics, than with newer antidepressants such as selective serotonin reuptake inhibitors (SSRIs).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of two randomized trials (n = 463) compared newer antidepressants (agomelatine or <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a>) plus antimanic drugs (eg, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> or <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>) with placebo plus antimanic drugs; pharmacotherapy was administered for 12 months [<a href="#rid56">56</a>]. The risk of new manic/hypomanic episodes was greater with adjunctive antidepressants than placebo (odds ratio 1.77, 95% CI 1.02-3.09).</p><p></p><p>Continuation and maintenance treatment with antidepressant monotherapy can cause new episodes of mania and hypomania. A meta-analysis of four randomized trials (n = 172 bipolar patients) lasting at least four months compared antidepressant monotherapy with antimanic drug monotherapy [<a href="#rid49">49</a>]. The risk of new manic/hypomanic episodes was greater in patients who received antidepressant monotherapy (relative risk 2.4, 95% CI 1.4-3.9).</p><p class="headingAnchor" id="H171998108"><span class="h2">Pharmacologic risk factors</span><span class="headingEndMark"> — </span>The risk of switching in patients with bipolar depression who are treated with antidepressants may vary according to the antidepressant class or specific drug that is used [<a href="#rid12">12</a>]. In addition, prescribing antidepressants in conjunction with antimanic drugs (eg, <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, or second-generation antipsychotics) may mitigate the risk of switching to mania/hypomania. (See <a class="local">'Using antimanic drugs to prevent switching'</a> above.)</p><p>Although case reports describe mania/hypomania following abrupt withdrawal of antidepressants, tapered discontinuation, or a decrease in dose [<a href="#rid73">73</a>], it is not known whether onset of mania/hypomania in these cases was due to withdrawal of antidepressants or the natural course of illness.</p><p class="headingAnchor" id="H20879365"><span class="h3">Antidepressant class and specific drugs</span><span class="headingEndMark"> — </span>It is not established whether the risk of treatment-emergent mania/hypomania varies among specific antidepressants because most drugs have not been compared in head-to-head trials. However, randomized trials suggest that switching polarity during treatment of acute bipolar depression occurs less often with <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> and more often with tricyclics or <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> [<a href="#rid3">3,12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bupropion</strong> – A meta-analysis of two trials, in 240 patients who were treated with antimanic drugs, found that switching occurred less often with <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> than <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a>, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, or <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> (relative risk 0.3, 95% CI 0.1-0.9) [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Citalopram</strong> – A one-year randomized trial compared <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">citalopram</a> (mean dose 27 mg/day) with placebo in 119 patients who were treated with antimanic drugs [<a href="#rid61">61</a>]. The rate of switching to mania or hypomania with adjunctive citalopram or placebo was comparable (5 and 10 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tricyclics –</strong> A meta-analysis of six trials (370 patients) found that switching occurred in more patients who received tricyclics (<a class="drug drug_general" data-topicid="9283" href="/z/d/drug information/9283.html" rel="external">clomipramine</a>, <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">desipramine</a>, or <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">imipramine</a>) than other antidepressants (<a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">fluvoxamine</a>, <a class="drug drug_general" data-topicid="10059" href="/z/d/drug information/10059.html" rel="external">moclobemide</a>, <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">paroxetine</a>, or <a class="drug drug_general" data-topicid="10012" href="/z/d/drug information/10012.html" rel="external">tranylcypromine</a>) (relative risk 2.9, 95% CI 1.3-6.7) [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">In addition, a pooled analysis (415 patients) found that switching occurred in more patients who received tricyclics than SSRIs or placebo (11 versus 4 and 4 percent) [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venlafaxine</strong> – Two trials found that among patients who received <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> plus antimanic drugs (combined n = 95), switching occurred in 15 percent [<a href="#rid75">75,76</a>]. In one of the trials, switching to mania or hypomania occurred more often with venlafaxine than <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> or <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a>, especially among patients with a history of rapid cycling [<a href="#rid75">75</a>].</p><p></p><p class="headingAnchor" id="H171999377"><span class="h2">Clinical risk factors</span></p><p class="headingAnchor" id="H3589011647"><span class="h3">Bipolar I and bipolar II disorder</span><span class="headingEndMark"> — </span>Switching from bipolar major depression to mania/hypomania during treatment with an antidepressant may be more likely to occur in patients with bipolar I disorder than bipolar II disorder [<a href="#rid12">12,70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of seven randomized trials and six prospective observational studies that compared antidepressant-induced mood elevation in bipolar I patients (n = 462) with bipolar II patients (n = 315), the risk of switching was greater in patients with bipolar I disorder (relative risk 2, 95% CI 1-3) [<a href="#rid77">77</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A subsequent observational study also found that the bipolar I subtype was associated with switching [<a href="#rid78">78</a>].</p><p></p><p>In addition, a 16-week trial randomly assigned patients with bipolar II major depression (n = 142) to one of three treatments: <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> plus placebo, <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> plus placebo, or lithium plus sertraline [<a href="#rid35">35</a>]. Switching to hypomania was comparable with lithium alone, sertraline alone, and lithium plus sertraline (19, 20, and 13 percent of patients); none of the patients switched to mania.</p><p class="headingAnchor" id="H3685385386"><span class="h3">Other</span><span class="headingEndMark"> — </span>Switching to mania during treatment with antidepressants has been associated with early age of onset of bipolar disorder, female sex, history of suicide attempts, symptoms of mania/hypomania concurrent with depression, and comorbid substance abuse and anxiety disorders [<a href="#rid24">24-29</a>]. However, these factors are not consistently associated with switching across multiple studies, and are likely to have little predictive power for any specific patient [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H20879407"><span class="h1">RISK OF RAPID CYCLING</span><span class="headingEndMark"> — </span>The possible risks of using antidepressants in bipolar depressed patients include increased mood cycle frequency and/or the development of rapid cycling, which is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Antidepressants'</a>.)</p><p class="headingAnchor" id="H2771094"><span class="h1">RISK OF SUICIDALITY</span><span class="headingEndMark"> — </span>For patients with bipolar depression, it is not clear if antidepressants cause new onset suicidal ideation and behavior. A review of prospective and retrospective observational studies found contradictory results [<a href="#rid12">12</a>]. Suicide deaths in particular are rare and thus difficult to examine in properly designed studies.</p><p>The risk of suicidal ideation and behavior in patients with unipolar major depression is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14672.html" rel="external">"Effect of antidepressants on suicide risk in adults"</a>.)</p><p class="headingAnchor" id="H2751922261"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of antidepressants</strong> – There is a limited role for antidepressants  (<a class="graphic graphic_table graphicRef53818" href="/z/d/graphic/53818.html" rel="external">table 1</a>) as adjuncts to antimanic drugs for treating patients with acute bipolar major depression. For bipolar major depression that remits with an antidepressant plus an antimanic drug, we generally continue antidepressants for approximately two to four months after remission of the depressive syndrome. However, we attempt to avoid maintenance treatment with antidepressants in patients with a current course of rapid cycling, a history of antidepressant-associated switch from depression to mania/hypomania or increases in mood cycle frequency, or a history of frequent and/or severe manic episodes. (See <a class="local">'Role of antidepressants'</a> above.)</p><p></p><p class="bulletIndent1">Clinicians should always prescribe an antidepressant in conjunction with an antimanic drug such as <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, or a second-generation antipsychotic and avoid antidepressant monotherapy. (See <a class="local">'Using antimanic drugs to prevent switching'</a> above and <a class="local">'Avoiding antidepressant monotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy of antidepressants</strong> – For patients with acute bipolar I or bipolar II major depression, short term (eg, 6 to 12 weeks) augmentation of antimanic drugs with antidepressants may be beneficial. The best established antimanic/antidepressant drug combination is <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">fluoxetine</a>. (See <a class="local">'Acute treatment'</a> above.)</p><p></p><p class="bulletIndent1">For patients with acute bipolar depression who are treated with an antidepressant plus an antimanic drug and then recover, maintenance treatment with adjunctive antidepressants may possibly reduce the risk of depressive relapses in some patients. (See <a class="local">'Maintenance treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of switching to mania</strong> – Switching polarity often occurs in bipolar disorder in the absence of antidepressant treatment, and the evidence indicates that acute treatment with adjunctive antidepressants may not increase switching from bipolar major depression to mania/hypomania. Nevertheless, the risk of treatment-emergent mania may exist for patient subgroups (eg, bipolar I disorder) and patients who are treated with antidepressant monotherapy. It is not clear if maintenance treatment with adjunctive antidepressants increases the risk of switching. (See <a class="local">'Risk of switching to mania'</a> above and <a class="local">'Clinical risk factors'</a> above.)</p><p></p><p class="bulletIndent1">Although it is not established whether the risk of switching varies according to specific antidepressants, the risk of mania/hypomania may be greater with tricyclics and serotonin-norepinephrine reuptake inhibitors than other drugs such as selective serotonin reuptake inhibitors (SSRIs). Across different acute randomized trials, the switch rate for <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">venlafaxine</a> was 15 percent, for tricyclics was 11 percent, and for SSRIs, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, or placebo was 3 to 5 percent. (See <a class="local">'Antidepressant class and specific drugs'</a> above.)</p><p></p><p class="bulletIndent1">If manic or hypomanic symptoms emerge during antidepressant treatment, antidepressants should be abruptly stopped and antimanic treatments should be optimized. (See  <a class="medical medical_review" href="/z/d/html/679.html" rel="external">"Bipolar mania and hypomania in adults: Choosing pharmacotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of rapid cycling</strong> – The possible risks of using antidepressants in bipolar depressed patients include increased mood cycle frequency and/or the development of rapid cycling. (See  <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">"Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Antidepressants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suicidal ideation and behavior</strong> – It is not clear whether antidepressants are associated with new onset suicidal ideation and behavior. (See <a class="local">'Risk of suicidality'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fountoulakis KN. An update of evidence-based treatment of bipolar depression: where do we stand? Curr Opin Psychiatry 2010; 23:19.</a></li><li><a class="nounderline abstract_t">Licht RW, Gijsman H, Nolen WA, Angst J. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand 2008; 118:337.</a></li><li><a class="nounderline abstract_t">Salvi V, Fagiolini A, Swartz HA, et al. The use of antidepressants in bipolar disorder. J Clin Psychiatry 2008; 69:1307.</a></li><li><a class="nounderline abstract_t">Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007; 58:85.</a></li><li><a class="nounderline abstract_t">Greil W, Häberle A, Haueis P, et al. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord 2012; 136:534.</a></li><li><a class="nounderline abstract_t">Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G. Treatment of bipolar depression: an update. J Affect Disord 2008; 109:21.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.</li><li><a class="nounderline abstract_t">Ghaemi SN. Treatment of rapid-cycling bipolar disorder: are antidepressants mood destabilizers? Am J Psychiatry 2008; 165:300.</a></li><li><a class="nounderline abstract_t">Yerevanian BI, Koek RJ, Mintz J, Akiskal HS. Bipolar pharmacotherapy and suicidal behavior Part 2. The impact of antidepressants. J Affect Disord 2007; 103:13.</a></li><li><a class="nounderline abstract_t">Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2011; 72:356.</a></li><li><a class="nounderline abstract_t">Frye MA, Ha K, Kanba S, et al. International consensus group on depression prevention in bipolar disorder. J Clin Psychiatry 2011; 72:1295.</a></li><li><a class="nounderline abstract_t">Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013; 170:1249.</a></li><li><a class="nounderline abstract_t">Thase ME. Antidepressants and rapid-cycling bipolar II disorder: dogma, definitions and deconstructing discrepant data. Br J Psychiatry 2013; 202:251.</a></li><li><a class="nounderline abstract_t">Vieta E, Garriga M. Adjunctive antidepressants in bipolar depression. Lancet Psychiatry 2016; 3:1095.</a></li><li><a class="nounderline abstract_t">Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30:495.</a></li><li class="breakAll">Ketter TA, Miller S, Wang PW, Culver J. Treatment of bipolar depression. In: Advances in Treatment of Bipolar Disorder, Ketter TA (Ed), American Psychiatric Publishing, Washington, DC 2015. p.17.</li><li><a class="nounderline abstract_t">Bobo WV. The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. Mayo Clin Proc 2017; 92:1532.</a></li><li><a class="nounderline abstract_t">Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97.</a></li><li><a class="nounderline abstract_t">Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010; 11:81.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Bipolar Disorder: The Assessment and Management of Bipolar Disorder in Adults, Children and Young People in Primary and Secondary Care. NICE Clinical Guideline 185. February, 2016. https://www.nice.org.uk/guidance/cg185 (Accessed on October 01, 2017).</li><li><a class="nounderline abstract_t">Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol 2017; 20:180.</a></li><li><a class="nounderline abstract_t">Ostacher MJ, Tandon R, Suppes T. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Bipolar Disorder: A Novel, Practical, Patient-Centered Guide for Clinicians. J Clin Psychiatry 2016; 77:920.</a></li><li><a class="nounderline abstract_t">Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49:1087.</a></li><li><a class="nounderline abstract_t">Goldberg JF, Perlis RH, Ghaemi SN, et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry 2007; 164:1348.</a></li><li><a class="nounderline abstract_t">Perlis RH, Ostacher MJ, Goldberg JF, et al. Transition to mania during treatment of bipolar depression. Neuropsychopharmacology 2010; 35:2545.</a></li><li><a class="nounderline abstract_t">Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disord 2003; 5:407.</a></li><li><a class="nounderline abstract_t">Frye MA, Helleman G, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009; 166:164.</a></li><li><a class="nounderline abstract_t">Post RM, Leverich GS, Nolen WA, et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord 2003; 5:396.</a></li><li><a class="nounderline abstract_t">Valentí M, Pacchiarotti I, Bonnín CM, et al. Risk factors for antidepressant-related switch to mania. J Clin Psychiatry 2012; 73:e271.</a></li><li><a class="nounderline abstract_t">Sachs GS, Dupuy JM, Wittmann CW. The pharmacologic treatment of bipolar disorder. J Clin Psychiatry 2011; 72:704.</a></li><li><a class="nounderline abstract_t">Bottlender R, Rudolf D, Strauss A, Möller HJ. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001; 63:79.</a></li><li class="breakAll">Rouillon F, LeJoyeux M, Filteau MJ. Unwanted effects of long-term treatment. In: Long-Term Treatment of Depression, Montgomery SA, Rouillon F (Eds), John Wiley &amp; Sons, Chichester 1992. p.81.</li><li><a class="nounderline abstract_t">Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356:1711.</a></li><li><a class="nounderline abstract_t">Viktorin A, Lichtenstein P, Thase ME, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 2014; 171:1067.</a></li><li><a class="nounderline abstract_t">Altshuler LL, Sugar CA, McElroy SL, et al. Switch Rates During Acute Treatment for Bipolar II Depression With Lithium, Sertraline, or the Two Combined: A Randomized Double-Blind Comparison. Am J Psychiatry 2017; 174:266.</a></li><li><a class="nounderline abstract_t">Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.</a></li><li><a class="nounderline abstract_t">Tamayo JM, Sutton VK, Mattei MA, et al. Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. J Clin Psychopharmacol 2009; 29:358.</a></li><li><a class="nounderline abstract_t">Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016; 387:1561.</a></li><li><a class="nounderline abstract_t">Vieta E. Antidepressants in bipolar I disorder: never as monotherapy. Am J Psychiatry 2014; 171:1023.</a></li><li><a class="nounderline abstract_t">Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction. J Affect Disord 2005; 87:121.</a></li><li><a class="nounderline abstract_t">Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148:910.</a></li><li><a class="nounderline abstract_t">Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol 2008; 28:171.</a></li><li><a class="nounderline abstract_t">Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4:313.</a></li><li><a class="nounderline abstract_t">Amsterdam JD, Lorenzo-Luaces L, Soeller I, et al. Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study. J Affect Disord 2015; 185:31.</a></li><li><a class="nounderline abstract_t">Amsterdam JD, Lorenzo-Luaces L, Soeller I, et al. Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate. Br J Psychiatry 2016; 208:359.</a></li><li><a class="nounderline abstract_t">Park JH, Nuñez NA, Gardea-Resendez M, et al. Short Term Second-Generation Antidepressant Monotherapy in Acute Depressive Episodes of Bipolar II Disorder: A Systematic Review and Meta-Analysis. Psychopharmacol Bull 2022; 52:45.</a></li><li><a class="nounderline abstract_t">McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.</a></li><li><a class="nounderline abstract_t">El-Mallakh RS, Vöhringer PA, Ostacher MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. J Affect Disord 2015; 184:318.</a></li><li><a class="nounderline abstract_t">Liu B, Zhang Y, Fang H, et al. Efficacy and safety of long-term antidepressant treatment for bipolar disorders - A meta-analysis of randomized controlled trials. J Affect Disord 2017; 223:41.</a></li><li><a class="nounderline abstract_t">Chessick CA, Dimidjian S. Screening for bipolar disorder during pregnancy and the postpartum period. Arch Womens Ment Health 2010; 13:233.</a></li><li><a class="nounderline abstract_t">Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157:1873.</a></li><li><a class="nounderline abstract_t">Hirschfeld RM. The mood disorder questionnaire: its impact on the field [corrected]. Depress Anxiety 2010; 27:627.</a></li><li><a class="nounderline abstract_t">Hirschfeld RM, Cass AR, Holt DC, Carlson CA. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract 2005; 18:233.</a></li><li><a class="nounderline abstract_t">Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.</a></li><li><a class="nounderline abstract_t">Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry 2010; 167:934.</a></li><li><a class="nounderline abstract_t">McGirr A, Vöhringer PA, Ghaemi SN, et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry 2016; 3:1138.</a></li><li><a class="nounderline abstract_t">Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011; 72:156.</a></li><li><a class="nounderline abstract_t">Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004; 161:1537.</a></li><li><a class="nounderline abstract_t">Vázquez GH, Tondo L, Undurraga J, Baldessarini RJ. Overview of antidepressant treatment of bipolar depression. Int J Neuropsychopharmacol 2013; 16:1673.</a></li><li><a class="nounderline abstract_t">Hu Y, Zhang H, Wang H, et al. Adjunctive antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis. Psychiatry Res 2022; 311:114468.</a></li><li><a class="nounderline abstract_t">Ghaemi SN, Whitham EA, Vohringer PA, et al. Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD): A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Psychiatry 2021; 82.</a></li><li><a class="nounderline abstract_t">Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand 2014; 130:452.</a></li><li><a class="nounderline abstract_t">Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67:1025.</a></li><li><a class="nounderline abstract_t">Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol 2009; 12:773.</a></li><li><a class="nounderline abstract_t">Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010; 71:372.</a></li><li><a class="nounderline abstract_t">Yatham LN, Arumugham SS, Kesavan M, et al. Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression. N Engl J Med 2023; 389:430.</a></li><li><a class="nounderline abstract_t">Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009; 11:453.</a></li><li><a class="nounderline abstract_t">Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010; 121:404.</a></li><li><a class="nounderline abstract_t">Daray FM, Thommi SB, Ghaemi SN. The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis. Bipolar Disord 2010; 12:702.</a></li><li><a class="nounderline abstract_t">Fountoulakis KN, Yatham L, Grunze H, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm. Int J Neuropsychopharmacol 2017; 20:121.</a></li><li><a class="nounderline abstract_t">McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158:420.</a></li><li><a class="nounderline abstract_t">Thompson WK, Kupfer DJ, Fagiolini A, et al. Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial. J Clin Psychiatry 2006; 67:783.</a></li><li><a class="nounderline abstract_t">Andrade C. Antidepressant-withdrawal mania:a critical review and synthesis of the literature. J Clin Psychiatry 2004; 65:987.</a></li><li><a class="nounderline abstract_t">Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164:549.</a></li><li><a class="nounderline abstract_t">Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006; 189:124.</a></li><li><a class="nounderline abstract_t">Vieta E, Martinez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002; 63:508.</a></li><li><a class="nounderline abstract_t">Bond DJ, Noronha MM, Kauer-Sant'Anna M, et al. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry 2008; 69:1589.</a></li><li><a class="nounderline abstract_t">Frye MA, McElroy SL, Prieto ML, et al. Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania. J Clin Psychiatry 2015; 76:174.</a></li></ol></div><div id="topicVersionRevision">Topic 14655 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19901836" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : An update of evidence-based treatment of bipolar depression: where do we stand?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18754834" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18681751" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The use of antidepressants in bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17215417" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22134044" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18037498" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of bipolar depression: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18037498" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment of bipolar depression: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316425" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Treatment of rapid-cycling bipolar disorder: are antidepressants mood destabilizers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17617467" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bipolar pharmacotherapy and suicidal behavior Part 2. The impact of antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20816033" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pharmacotherapy for the treatment of acute bipolar II depression: current evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22075097" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : International consensus group on depression prevention in bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24030475" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23549940" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antidepressants and rapid-cycling bipolar II disorder: dogma, definitions and deconstructing discrepant data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28100424" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Adjunctive antidepressants in bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979387" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979387" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28888714" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20148751" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20148751" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941079" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26580001" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Bipolar Disorder: A Novel, Practical, Patient-Centered Guide for Clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643054" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17728419" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20827274" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Transition to mania during treatment of bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14636364" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Antidepressant-induced mania: an overview of current controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19015231" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14636363" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22401488" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk factors for antidepressant-related switch to mania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21658351" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The pharmacologic treatment of bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11246083" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11246083" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17392295" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effectiveness of adjunctive antidepressant treatment for bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24935197" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28135846" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Switch Rates During Acute Treatment for Bipolar II Depression With Lithium, Sertraline, or the Two Combined: A Randomized Double-Blind Comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14609883" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19593175" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26388529" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25272338" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antidepressants in bipolar I disorder: never as monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15923042" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2053632" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Tranylcypromine versus imipramine in anergic bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18344727" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2607128" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26143402" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26892848" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35721812" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Short Term Second-Generation Antidepressant Monotherapy in Acute Depressive Episodes of Bipolar II Disorder: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20122366" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26142612" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28715727" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy and safety of long-term antidepressant treatment for bipolar disorders - A meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20198393" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Screening for bipolar disorder during pregnancy and the postpartum period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11058490" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20583140" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The mood disorder questionnaire: its impact on the field [corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994469" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Screening for bipolar disorder in patients treated for depression in a family medicine clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556941" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The PHQ-9: validity of a brief depression severity measure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20478876" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Illness risk following rapid versus gradual discontinuation of antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28100425" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21034686" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337640" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Antidepressants for bipolar depression: a systematic review of randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23428003" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Overview of antidepressant treatment of bipolar depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35248807" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Adjunctive antidepressants for the acute treatment of bipolar depression: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33434956" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Citalopram for Acute and Preventive Efficacy in Bipolar Depression (CAPE-BD): A Randomized, Double-Blind, Placebo-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25283309" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16889444" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19079815" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20409444" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37530824" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624385" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19958306" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Mania associated with antidepressant treatment: comprehensive meta-analytic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21040287" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27816941" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11229983" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16841628" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: analysis of acute-phase data from a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15291689" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Antidepressant-withdrawal mania:a critical review and synthesis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8038948" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16880481" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12088162" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19192442" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25611077" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
